. Thus, the remarkable phenotypic diversity of b-thal reflects not only the heterogeneity of mutations in the HBB locus, but also the concomitance of other genetic factors that alter the production of free a-chains, but there are still many phenotypic variations in b-thal patients whose causes remain unknown. It is therefore difficult to take into account a complete genomic approach to all these factors and there is still a need for a phenotypic indicator to help a targeted approach of genomic variability.
Recently we have designed a new test for the measurement of soluble a-Hb (a-Hb pool) directly from lysed RBCs (Vasseur et al, 2011) . Up to now, excess free a-Hb or b-Hb has been distinguished by the presence of inclusion bodies in cytology corresponding to denatured or precipitated Hb, but this approach is only qualitative and has low sensitivity and specificity. Many studies with radioactive tracing have shown both a cytosolic soluble a-chain pool present in the RBCs, and an insoluble a-chain fraction in the membrane of b-thalassemic erythrocytes (Rouyer-Fessard et al, 1989) . The design of our rapid quantitative method for the measurement of the a-Hb pool is based on the specificity of the interaction between the Alpha-Haemoglobin Stabilizing Protein (AHSP) and a-Hb. The AHSP is the chaperone of a-Hb and forms a heterodimer with the soluble a-Hb, stabilizing it until it combines with its partner b-Hb chain. AHSP specifically binds to a-Hb, but not to b-Hb or HbA (Kihm et al, 2002; Baudin-Creuza et al, 2004) .
Others approaches using quantitative real-time PCR have showed a significant differences of the HBA/HBB mRNA globin ratio in reticulocytes between control and b-thal groups (Ranjbaran et al, 2013) . The direct measurements of a/non a-globin biosynthetic or HBA/non HBA mRNA ratios are difficult to obtain routinely and they also only reflect the reticulocyte stage. Currently, we have no means to quantitatively appreciate the global bone marrow disequilibrium in a/non a-globin chain biosynthesis.
The excess of unpaired a-Hb in b-thal is actively degraded via several pathways, including both ubiquitin proteasome system and autophagy pathways, and accumulate mainly in the late stages of erythroid maturation (Khandros & Weiss, 2010; Khandros et al, 2012) , causing a number of pathological symptoms, such as premature destruction of immature erythroid precursors in the bone marrow (ineffective erythropoiesis), anaemia and haemolysis (Thein, 2005) . The circulating RBCs are less affected by the a-globin excess either because of the uneven cellular distribution of c-globin residual synthesis or, presumably, by genetic individual differences in proteolysis, apoptosis, or defence capacity against oxidative stress.
A large body of pharmacological, clinical, genetic and experimental evidence suggests that altering the globin chain imbalance by reducing the production of a-globin synthesis ameliorates the disease severity in patients with b-thal (Mettananda et al, 2015) prompting the study of the a-Hb pool.
The aim of the present study was to evaluate the performance of the a-Hb pool measurement in order to confirm its capacity to discriminate between b-thal and non-b-thal subjects, provide a new biomarker for the clinical monitoring of thalassemic patients and aid diagnostic orientation.
Subjects and Methods

Subjects and study design
This study (ClinicalTrials.gov identifier: NCT 02855957) is a case-control study of thalassaemia patients and healthy volunteers recruited by the Henri Mondor Hospital, France. The subjects were at least 18 years old. Fifty healthy volunteers were recruited as controls through the donor base of the hospital regardless of ethnic origin. Eighty-two patients were recruited at the Unit e des Maladies G en etiques du Globule Rouge (UMGGR) of the same hospital: 58 b-thal patients with different phenotypic expression of the disease and 24 athal patients. Informed written consent was obtained from all subjects in accordance with the Declaration of Helsinki. Patients were already monitored in the hospital for their pathology or had been sent by their physician for a diagnosis. The exclusion criteria for all subjects were as follows: transfusion in the previous 3 months, active chronic viral disease (hepatitis B, C, human immunodeficiency virus), current infections or known inflammatory pathologies, hyperor hypothyroidism, active tumour pathology or in remission for less than 5 years, receiving oral corticosteroids, haemoglobinopathy other than thalassaemia, treated by an erythropoiesis stimulating agent or hydroxycarbamide for more than 3 months and (for the volunteers) to be unrelated haemoglobinopathy carriers. All subjects and their data were pseudo-anonymized in accordance with good clinical practice. The study protocol was approved by an institutional review board.
Data investigations and molecular analysis
Eighteen ml of whole peripheral blood were collected as EDTA-anticoagulated venous blood samples for haematological and molecular analysis. The clinical, enzymatic and haematological data were collected from different laboratories of the hospital. Hb analyses were carried out with by Variant II cation exchange chromatography (BioRad, Hercules, CA, USA).
Genomic DNA was extracted from peripheral blood using a DNA extraction kit and according to the manufacturer's instructions (Maxwell â 16 Blood DNA Purification Kit, Promega Corporation, Madison, WI, USA). HBB genotype was determined by direct sequencing of globin genes. In homozygous patients, large deletion on the HBB locus were sought using semi quantitative polymerase chain reaction (PCR). The HBA locus was investigated by a sequential procedure including a direct search for the aÀ3Á7 a-Haemoglobin Pool As Monitoring Biomarker for Thalassemic Patients ª 2017 John Wiley & Sons Ltd trait and anti 3Á7 by GAP-PCR. The anti 4Á2 triplication was determined by GAP-PCR on-demand. The search of the most common a-locus deletions and point mutations was done using a reverse dot blot Kit (a-globin Strip Assay, ViennaLab, Vienna, Austria) and the direct sequencing of the HBA1 and HBA2 genes (Rose et al, 2009 ).
Preparation of haemolysates and in vitro a-Hb pool measurement
Blood samples from each subject were centrifuged for 5 min at 4°C. The plasma was gently removed, leaving 3 mm above the RBCs in order to keep the reticulocytes. RBC samples were processed within 2 h of blood collection. RBCs were washed with 0Á15 mol/l NaCl then lysed with cold distilled water. After centrifugation, the RBC lysate (haemolysate) was recovered and stored at À80°C.
The haemolysates were then deposited on glutathione Sepharose 4B-coated 96-well filter plates (GST MultiTrap 4B, GE Healthcare Lifescience, Uppsala, Sweden) on which recombinant glutathione S transferase-AHSP (GST-AHSP) was beforehand bound, this protein only trapping the free soluble a-Hb (Vasseur et al, 2011) . The quantity of a-Hb in eluted GST-AHSP/a-Hb complex and the total Hb contained in the haemolysate were determined by spectrophotometry from the Soret band (414 nm, on a haem basis). The a-Hb pool is expressed in ppm, equivalent to ng a-Hb/mg of total Hb subunits per ml of haemolysate.
Statistical analyses
Descriptive statistics, including percentages (%), mean and standard deviation (SD) were used to describe the general characteristics of the subjects. Due to nonparametric data distribution, differences for continuous variables between groups were established by Kruskal-Wallis analysis followed by Dunn's post-test with a Bonferroni adjustment for multiple comparisons. The comparison of the gender variable between groups was assessed using the chi-square test. A receiver operating characteristic (ROC) analysis was conducted to calculate the area under the curve (AUC) with 95% confidence interval (CI) for a-Hb pool with the best cut-off values capable of identifying b-thal patients. Potential relationhips between the a-Hb pool and biological parameters were analysed by Spearman's rho and Pearson correlation coefficients. Due to the asymmetrical distribution, logarithmic transformation was performed on a-Hb pool values. In order to evaluate parameters that influence the a-Hb pool levels, we used linear regression analysis after log transformation of a-Hb pool values. The interaction of all variables with the log a-Hb pool values was appraised using a stepwise multivariate analysis; if there was significant correlation between independent variables, only one was entered into the model to avoid multicollinearity. Two-tailed P < 0Á05 were considered significant. Statistical analyses were performed using Stata/Se version 12.0 software (StataCorp LP, College Station, TX, USA).
Results
Globin genotypes and a-Hb pool in healthy volunteers and thal patients
Among the 50 healthy volunteers recruited, 1 had all clinical, enzymatic and haematological data missing, and 11 had an abnormal HBA or HBB genotype (22%). The 38 healthy volunteers without abnormalities of HBA1/HBA2 and HBB genes were used as controls for this study. The mean (AESD) of the a-Hb pool in controls was 81 AE 15 ppm and the range varied from 54 to 115 ppm (Fig 1A, B) .
Among 58 recruited b-thal patients, DNA analysis identified 24 different b-thal mutations (Table I) . A total of 50% of the identified alleles can be grouped into 3 different mutations [HBB:c.118C>T (codon 39 (C>T)) n = 12, HBB: A patient, who may not be considered as b-thal, a total of 57 b-thal subjects were classified mainly as heterozygous (n = 35) and compound heterozygous (n = 13), with only 8 patients having homozygous b-thal. Four patients had a deletion in the HBB locus, 1 (Patient 82) was homozygous and 3 were heterozygous (Patients 68, 69 and 84). Screening for the concomitant inheritance of a-thal revealed 7 subjects with heterozygous a + -thal trait (a À3Á7 /aa) (12%) and interestingly, 6 subjects were found to carry a HBA triplication (aa/aaa anti 3Á7 or aa/ aaa anti 4Á2 ) (10%). The range of the a-Hb pool in b-thal patients with or without abnormality in HBA genes varied from 72 to 3699 ppm (Table I , Fig 1A) . The highest value was observed in a patient with b E /b 0 thal and the lowest value was found in a patient who was heterozygous for HBB: Table I . b-and a-globin mutations in b-thal patients. The a-Hb pool is expressed in ppm, equivalent to ng a-Hb/mg of total Hb subunits per ml of haemolysate. HGVS, Human Genome Variation Society; HO, homozygous; HR, heterozygous; *, Hb Monroe; **, undescribed mutation; s, splenectomized patient. c.-136C>G (-86(C>G)) mutation. Whenever 3 different mutations were in presence of a HBA gene triplication, the a-Hb pool value was increased. The a-Hb pools were higher in 10 b-thal patients who had been splenectomized more than 7 years previously compared to non-splenectomized patients with the same phenotypes ( (Table I) . Table II summarizes the HBA and HBB genotypes detected in a-thal patients. Among the 24 a-thal patients recruited, 18 patients were a-thal without an associated b mutation (75%), 5 patients had an associated b mutation (21%) and 1 was homozygous for Hb Taybe (HBA1: c.118_120delACC) which is an unstable Hb and consequently was excluded from the study. The South-East Asian (SEA) (-SEA ) and aÀ3Á7 kb deletions were most common anomalies affecting a-thal patients in our study. The compound heterozygous for SEA and aÀ3Á7 of the a-globin genes (-SEA /-a À3Á7 ) was the most common Hb H disease (n = 10).
Three patients with -SEA /aa CS were also identified. The aHb pool in all a-thal patients with or without an abnormality in the HBB gene varied from 22 to 81 ppm depending on the number of a genes, regardless of the case of Hb Taybe (ppm = 523) (Fig 1B) . It should be noted that in patients with Hb H disease (n = 11) the mean of a-Hb pool was 32 AE 7 ppm.
Characteristics of studied populations
The biological data for the 81 patients (58 b-thal and 23 athal patients) and 38 controls were summarized in Table III . No difference was found between the three groups in terms of age and sex (P > 0Á05). By Bonferroni-Dunn test, only 2 parameters, the RBC count and the HbA 2 percentage, showed statistically significant differences in the 3 groups, with a mean value significantly decreased in the control group (P < 0Á05). In b-thal group, all haematological and enzymatic data showed statistically significant differences to the control group (P < 0Á05), except for white blood cells (WBC), platelet counts and C-reactive protein. The data of a-thal group showed statistically significant differences to the control group (P < 0Á031), except for WBC, platelet counts, lactate dehydrogenase (LDH), serum ferritin, C-reactive protein, pyrimidine 5 0 nucleotidase (P5N) and HbF. Statistically significant differences between the b-and a-thal groups were observed only for 5 parameters: RBCs (P < 0Á0066), LDH (P < 0Á0035), HbA 2 (P < 0Á0001), HbF (P < 0Á0001) and dense cells (cell percentage defined as having a density up to 1Á110 g/ml from the RBC density distributions) (P < 0Á0001). These parameters were significantly lower in athal group compared to b-thal group except for RBCs, which was significantly increased. No patient had hydroxycarbamide therapy. However, 7 patients required a thalassaemia-related treatment, 1 receiving one injection of erythropoietin (300 mg) 1 month prior to collection and 6 treated with an iron chelating agent (deferiprone or deferasirox).
Sensitivity and specificity of the a-Hb pool measurement for predicting b-thal
The comparisons of a-Hb pool in a-and b-thal patients and controls are shown in Fig 1A. Statistical analysis by the Kruskal-Wallis test followed by multiple comparisons showed that the three groups of subjects were significantly different (P < 0Á003).
From the 38 controls and 80 recruited patients (57 b-thal and 23 a-thal patients), we determined the sensitivity, specificity and accuracy of the a-Hb pool measurement for defined as having a density up to 1Á110 g/ml from the RBC density distributions.
*n = 37, **n = 29, ***n = 36.
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predicting b-thal with a threshold ≥ 120 ppm (Table IV) . The sensitivity and specificity were 86% and 100%, respectively, in the 57 b-thal patients. The ROC curve and the AUC were used to evaluate the accuracy of a-Hb pool measurement in order to discriminate between b-thal and nonb-thal populations ( Figure S1 ). The ROC curve provided an AUC of 0Á9788, suggesting good discrimination ability. Eight b-thal patients overlapped with the controls (Fig 1B) . Among these 8 patients, all heterozygotes, 3 were heterozygous for a + -thal trait (a À3Á7 /aa), 7 had an increased HbA 2 (between 3Á8% and 6Á2%) and 1 subject (Patient 84) had normal HbA 2 but had a high level of HbF (21Á8%), which may correspond to a db-thal syndrome. The a-Hb pool values surrounding the area of overlap between only b-thal and a-thal patients are shown in Table V . The a-Hb pool measurement did not distinguish between 1 b-thal (Patient 77) and 2 a-thal subjects (Patients 34 and 86). Among the 4 b-thal patients in this area, Patient 62 was heterozygous for a + -thal trait (a À3Á7 /aa), which clearly decreased the a-Hb pool value compared to the 6 patients carrying the same mutation without a-thal trait (Table I) . It is worth noting that these 4 b-thal patients had increased HbA 2 levels and were unambiguously diagnosed as b-thal carriers. We also noted that Patient 21, carrying an undescribed HBB mutation was related to Patient 19 with the same mutation but the latter has a higher a-Hb pool value (Table I) . For the 2 a-thal patients in the overlap area, Patient 86 was heterozygous for Hb E which tends to increase the a pool and has aa CS /aa CS as HBA genotype, which leads to unstable Hb Constant Spring behaving as a non-deletional a-thal phenotype due to an impaired binding with AHSP (Turbpaiboon et al, 2006 Distribution of a-Hb pool in b-thal patients according to b and a-globin status
The distribution of the a-Hb pool in b-thal patients based on their phenotype is shown in Fig 2. The 57 b-thal patients were divided into 7 groups. All homozygous patients for bthal mutations and b-thal patients carrying a b E mutation as well as heterozygous b-thal patients with a a-gene triplication had a-Hb pool values >120 ppm. In b 0 -thal heterozygous patients, the simultaneous presence of a heterozygous a + -thal trait appears to decrease the a-Hb pool value. We noted that, the more the mutation caused severe clinical forms, the more the a-Hb pool increased. The number of subjects within most categories was, however, too small to support meaningful statistical tests. 
Relationship between haematological and enzymatic parameters and a-Hb pool in b-thal patients
Correlations between the a-Hb pool and 25 clinical and haematological characteristics of b-thal patients were analysed by Spearman's rho and Pearson correlation coefficients (Table S1 ). In univariate analysis, 9 parameters had correlation coefficients greater than 0Á70 with a-Hb pool values: Hb, MCHC, platelets, reticulocyte percentage, red cell distribution width (RDW), total bilirubin, R60 (middle density range in which 60% of the cells are found), red cell hexokinase activity (HK) and transferrin receptor. After log transformation of a-Hb pool values, a linear relationship between log a-Hb pool and these parameters were observed (Figs 3 and S2), the most significant association being observed with HK (r 2 =0Á8154, P < 0Á0001). There was no significant interaction between the splenectomy of patients and these different parameters with respect to a-Hb pool. Regarding all parameters, the multivariate analysis (Table S1) showed significant positive associations between log a-Hb pool values and HK, RDW, reticulocyte percentage and R60. This statistical model accounts for about 92% of variability of the aHb pool in b-thal patients.
Discussion
The major factor affecting the clinical severity of b-thal can be related to the deleterious effects of the imbalance between a-and non-a globin chain synthesis on erythroid maturation and survival. The extent of this imbalance leading to variable excess of unbound a-Hb reflects all possible combinations of HBA and HBB genotypes, levels of HbF and other genetic modifiers.
In a preliminary study, we evaluated the excess of a-Hb or a-Hb pool in 20 b-thal patients and 6 a-thal patients by a quantitative method applied directly to RBCs (Vasseur et al, 2011) . The term "a-Hb pool" corresponds to the soluble aHb that is not bound to the b-chain in RBCs but could be linked to AHSP.
The present study confirms that a-Hb pool measurement, performed on 57 non transfusion-dependent b-thal patients, 23 a-thal patients and 38 controls subjects, enables discrimination between b-thal patients and a-thal patients that could allow a rapid orientation of further DNA analysis. In b-thal and a-thal, a microcytosis is observed, and the a-Hb pool parameter fully discriminates a-from b-thalassaemia. Classical b-thal carriers have typically reduced red cell indices (MCV < 80 fl, MCH < 27 pg) with high RBCs, contrasting with the slightly lowered Hb levels and elevated HbA 2 (4-8%) and, often, Hb F levels. However, a few b-thal heterozygotes fail to manifest these classical haematological features and are termed as silent carriers having normal or borderline HbA 2 levels (Paglietti et al, 2016) . a-thal carriers can also escape diagnostic hypothesis, having a normal MCV or being confused with iron deficiency. The a-Hb pool measurement could direct the molecular genetic investigations, allowing a faster and accurate diagnosis, which may be critical in some genetic counselling situations (Table VI) .
The use of our novel test as an adjunct to the diagnostic methods was demonstrated in the present study in 2 circumstances. The first concerned patients with different a-Hb pool values although having the same HBB mutation and no apparent HBA1/HBA2 mutation. Thus, for the 2 patients with heterozygous HBB:c.316-197C>T mutation (Patients 12 and 57), the very high a-Hb pool value of one patient (Table I ). The second situation concerned patients recruited as b-thal but with normal HBA and HBB genotypes. The values of the a-Hb pool higher than the values of the control patients suggested the presence of a b-thal. In-depth analysis of the HBB genotype showed a large deletion of the HBB gene in the heterozygous state (Patients 68, 69 and 84) . Even for patients initially considered without an apparent Hb disorder, the precision of this test was exemplified in the previous study, when two patients who were initially considered as controls were found to have free a-Hb pool values lower (33 ppm) and higher (138 ppm) than the normal range. Genotyping of these patients showed that the first carried a a-thal mutation (a ivs1-5nt a/aa), while the second patient had a a-gene triplication (Table VI) (Vasseur et al, 2011) .
We also observed some b-thal patients with the same globin genotype, such as patients with HBB:c.228insA fs, stop+16 mutation (Patients 19 and 21) and similar HbA 2 or Hb F levels but with different a-Hb pool values promoting the idea that the a-Hb pool is not only related to the causal globin gene mutations but may reflect other genetic abnormalities that remain to be discovered.
However, although HbA 2 and/or HbF indicated a b-thal clinical picture, 8 b-thal patients in this study exhibited a a-Hb pool value similar to those observed in controls. An analysis of possible modulating factors of these b-thal patients would be to extensively screen the entire HBA family locus, as well as AHSP gene (Lai et al, 2006; Sagar et al, 2015) . If HbF is significantly elevated, XmnI restriction site of the HBG2 gene (Bandyopadhyay et al, 2001; Nguyen et al, 2010) or KLF1 gene mutations (Borg et al, 2010; Liu et al, 2014) , polymorphism in BCL11A gene or HBS1L-MYB intergenic region Uda et al, 2008; Wahlberg et al, 2009) should be investigated. It should be noted that the only a-thal-like phenotype patient recruited with a very high a-Hb pool was homozygous for an unstable Hb variant, Hb Taybe, caused by a deletion of one codon in the HBA1 gene. Usually asymptomatic or with minimal haematological abnormalities in the heterozygous state, Hb Taybe becomes clinically severe in homozygous patients (Galacteros et al, 1994) . Globin biosynthetic studies revealed a a/b-globin ratio in the range of bthal trait, requiring investigation of HBA and HBB genes (Paglietti et al, 2012) . The high a-Hb pool value in this patient is therefore in agreement with the globin biosynthesis found in the literature. This paradoxical result in globin biosynthesis has been reported for other unstable a-globin variants (Wajcman et al, 1993) , some of which can be explained by an impaired interaction with AHSP (BaudinCreuza et al, 2009). Different studies suggest that AHSP could be a genetic modifier of b-thal (Weiss et al, 2005) . Although there are arguments for both sides, no correlation was found between AHSP expression and the haematological parameters in b-thal patients (Mahmoud et al, 2015) but the AHSP expression level was significantly correlated to MCV, % HbF, a-globin, b-globin and excess a-globin expression in HbE/b-thal patients (Lim et al, 2012) .
We have also identified a a-Hb pool threshold of 120 ppm that had a high overall accuracy for predicting the presence of a homozygous b-thal, compound heterozygous or heterozygous b-thal associated with triplication of a globin genes. The wide dispersion of the a-Hb pool observed in b-thal patients reflects the broad clinical spectrum of this disease, ranging from asymptomatic to severe symptoms, which also depend on the default combination of the HBB gene with other abnormalities of Hb. This outcome highlights the role of the a-Hb pool as a result of various factors modulating the global imbalance of the bone marrow in the biosynthesis of the a/non-a globin chain which ultimately determines the b-thal phenotype.
We demonstrated for the first time that the a-Hb pool was significantly correlated with 9 haematological parameters of b-thal in univariate analysis, especially Hb, MCHC and reticulocyte percentage, which are modified in b-thal. There were no significant gender differences in those parameters. In multivariate analysis, the a-Hb pool is associated with HK, RDW, reticulocyte percentage and R60, with the most significant association observed with HK. Those parameters are known to be increased in b-thal patients compared to controls, as previously described (Ramot et al, 1969; Aslan et al, 2002) . HK activity is agedependent in the RBCs (Chapman & Schaumburg, 1967) , and it has been shown to be higher in thal, indicating a population with a younger mean cell age (Ramot et al, 1969) . The reticulocyte percentage is also well known to reflect the degree of the severity of b-thal, and the RDW and R60 characterize the degree of heterogeneity in RBC volumes and densities, respectively.
New therapies aiming at reducing a-globin chain overload in b-thal patients (Mettananda et al, 2015) could be monitored by a pool measurements. This is the case of Sotatercept (ACE-011), an activin receptor ligand trap, which may partially rescue inhibition of erythroid differentiation by bone marrow stromal factors (Iancu-Rubin et al, 2013) . Another study in mouse model of b-thalassemia suggested that ineffective erythropoiesis could be tackled by a mouse version of Sotatercept that reduced erythroid progenitor expansion (Dussiot et al, 2014) . The erythrocytes from treated mice had increased levels of soluble Hb and decreased levels of a-globin precipitates in erythrocytes. The a-and b-globin chain imbalance was also improved by a reduction in a-globin expression. Clinical studies testing Sotatercept benefits in human are currently underway (ClinicalTrials.gov identifier: NCT01571635).
In conclusion, we explored a new alternative and efficient tool to help a more targeted approach to genomic variability of b-thal by measuring the a-Hb pool. We have demonstrated that the a-Hb pool reflects not only the causal mutations but also the concomitance of other genetic factors that alter the production excess of free a chain. A a-Hb pool threshold >120 ppm is predictive of a TI status. The fact that the a-Hb pool was strongly associated with parameters known to reflect the degree of the severity of b-thal, and was overall higher in non-transfused splenectomized b-thal patients, confirm its role as a biomarker of the pathophysiology of TI. These findings suggest that this assay may be applied to follow the evolution of the a/non-a globin chain imbalance in response to different kind of treatments (Table VI). volunteers; F.G was in charge of the selection of patients; C.B and B.G managed the samples, carried out the lysates of RBCs and the DNA samples of patients and healthy volunteers; P.L-C was in charge of the selection of healthy volunteers, supervised data collection and supported the quality approach of the study. A.R provided clinical-trial support; S.P performed the globin locus studies; V.B-C analysed the data; V.B-C, C.V and F.G conceived and designed the study and wrote the paper. All authors reviewed, revised and approved the final version of the manuscript.
Conflict-of-interest disclosure
All authors have no conflicts of interest to declare.
Supporting Information
Additional Supporting Information may be found in the online version of this article: Table S1 . Influence of haematological and enzymatic data on a-Hb pool in b-thal patients. Fig S1. ROC curves for a-Hb pool to discriminate between b-thal and no b-thal population (a-thal patients and controls) with a cut-off of 120 ppm. 
